Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NMD Pharma A/S
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants must be 18 to 70 years inclusive at the time of signing the ICF.
Diagnosis of CMT type 1 or 2 confirmed by genetic testing.
Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg
Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Participant is capable of and has given signed informed consent
You may not be if
Participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular diseases) and/or ability to complete the tests, in the opinion of the Investigator.
Participants with laboratory test result abnormalities at screening considered clinically significant by the Investigator.
Participants who have received treatment with another IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1.
Participants with history of poor compliance with relevant therapy in the opinion of the Investigator.
Female participants who plan to become pregnant during the study or are currently pregnant or breastfeeding.
Clareo Health | Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
